Can this utility electrify your earnings?
The utility opts for regulation over generation.
Market-lagging returns could be written in this 1-Star.
While other big pharmas are spinning out businesses, Merck stays on course.
What are the biggest overhangs facing this biotech company?
Congress provided a two-for-one deal for smart investors.
Does Antares have the products to power your portfolio in 2013?
On the first day of the new Abbott, what should you watch for this revamped company's future?
As the Supreme Court moves forward considering pay-for-play, the specific impacts are dependent on the specific company’s role in the industry.
The Supreme Court's investigation of brand-name and generic drug maker’s agreements involves two significant areas of law.